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Abstract. Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin com-
ponent and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and
P. falciparummultidrug resistance 1 (pfmdr1) genes are associatedwith decreased sensitivity to amodiaquine and lumefantrine,
but effects of these polymorphisms on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-
lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled
by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients
were analyzed to assess relationships between parasite polymorphisms in pfcrt and pfmdr1 and clinically relevant outcomes
after treatment with AL or ASAQ. Presence of the pfmdr1 gene N86 (adjusted hazards ratio = 4.74, 95% confidence
interval = 2.29 – 9.78, P < 0.001) and increased pfmdr1 copy number (adjusted hazards ratio = 6.52, 95% confidence interval =
2.36–17.97, P < 0.001) were significant independent risk factors for recrudescence in patients treated with AL. AL and
ASAQ exerted opposing selective effects on single-nucleotide polymorphisms in pfcrt and pfmdr1. Monitoring selection
and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination
therapies; determination of the prevalence of at least pfcrtK76T and pfmdr1N86Y should now be routine.
INTRODUCTION
Recent successes in malaria control have depended on the
use of highly efficacious artemisinin combination therapies
(ACTs) for first-line treatment of uncomplicated Plasmodium
falciparum malaria. Adequate clinical and parasitologic cure
by ACTs relies on the rapid reduction in parasite biomass by
the potent, short-acting artemisinin component1–3 and the
subsequent elimination of residual parasites by the longer-
acting partner drug. The two most commonly used ACTs
worldwide are artemether-lumefantrine (AL) and artesunate-
amodiaquine (ASAQ).4 Polymerase chain reaction (PCR)–
adjusted efficacy for both combinations remains high in most
regions.5–7 However, there have been some reports of
decreasing AL cure rates in Africa8–11 and Asia,12 and reports
of high levels of treatment failures of ASAQ.13–18 Resistance
to ACT partner drugs has historically manifested before that
of artemisinins, whose short half-lives result in the exposure
of residual parasites to sub-therapeutic levels of the partner
drug alone. Response to the partner drug is therefore a key
component of overall ACT efficacy.
Mutations in the gene encoding the P. falciparum chloro-
quine resistance transporter (pfcrt) are associated with chlo-
roquine resistance19; a change from lysine to threonine at
codon 76 in pfcrt predicts responses of parasites to chloro-
quine.20,21 In the presence of pfcrt 76T, chloroquine resistance
is modulated by point mutations in the gene that encodes the
P. falciparum multidrug resistance transporter 1 ( pfmdr1),
primarily at codon 8622,23 and also by mutations at positions
184, 1034, 1042, and 1246.24 Decreased susceptibility to lume-
fantrine has been linked to polymorphisms in these two
genes.25–35 Increased pfmdr1 copy number, which confers
resistance to mefloquine,36 has also been associated with
reduced susceptibility to lumefantrine.37–40
Some studies of amodiaquine have reported reduced in vivo
response41–43 and increased 50% inhibitory concentration
values in vitro, in association with the presence of pfmdr1 86Y
and pfcrt 76T alleles.44,45 Selection of these alleles in recurrent
parasites after treatment with amodiaquine alone or in com-
bination with artesunate has been observed in a number of
studies.28,46–51 It has also been suggested that parasites that
carry chloroquine-resistant pfmdr1 alleles may be more suscep-
tible to artesunate in classical in vitro assays,24,52 an effect that
could counteract the increased risk of amodiaquine failure
when these drugs are combined in ASAQ.
Currently, AL and ASAQ retain high clinical efficacy with
few recrudescent infections, and individual studies generally
lack sufficient statistical power to assess the association between
parasite genotypes and outcomes of clinical treatment. Such
an assessment is a critical step in validating molecular changes
in parasite populations as useful markers of early signs of chang-
ing parasite susceptibility to lumefantrine or amodiaquine.
To overcome these challenges, individual patient data on
in vivo antimalarial efficacy and molecular markers of
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P. falciparum from 31 clinical trials were standardized,
pooled, and > 7,000 patient responses were analyzed to deter-
mine whether patients infected with parasites that carry these
polymorphisms are at increased risk of treatment failure. This
large data set also provided the opportunity to examine the
effects of AL and ASAQ treatment on selection in parasites
of particular alleles of pfcrt and pfmdr1.
METHODS
Selection and inclusion of data. Prospective clinical efficacy
studies of P. falciparum treatment with AL (six-dose regimen)
or ASAQ (three-day fixed dose or loose/co-blistered regi-
men) with a minimum of 28 days of follow-up and genotyping
of pfcrt and/or pfmdr1 were sought for the analysis. Studies
were identified by a systematic PubMed literature review
using the search terms (artesunate AND amodiaquine) OR
(artemether AND lumefantrine) OR (ACT) AND ( pfmdr1
OR pfcrt). Abstracts and text were screened to determine
whether inclusion criteria were met. Nine unpublished data-
sets were also solicited and included in the analysis (see
Supplemental Table 3). Individual anonymized patient data
including baseline characteristics, drug intake, parasite density
and temperature were collected. All but one study included
parasite genotyping to identify recrudescent infections of
P. falciparum, and all studies assessed the presence of pfcrt
and/or pfmdr1 polymorphisms (single nucleotide polymor-
phisms (SNPs) and copy number variation) in parasites isolated
from patients on day 0. Multiplicity of infection and molecular
resistance marker data from other days including the day of
microscopic recurrent parasitemia were included but were not
a prerequisite for study inclusion. Metadata on study location,
study design, drugs, and dosing regimens were also gathered.
A schematic of the patient numbers and overall flow of the
study is shown in Figure 1.
Data curation and generation of variables. All data sets
were uploaded to the WorldWide Antimalarial Resistance
Network repository and standardized by using the WorldWide
Antimalarial Resistance Network Data Management and Sta-
tistical Analysis Plans (DMSAP).53,54 Outcome status and
censoring were defined according to the Clinical DMSAP.53
Parasites that recurred within the follow-up period were clas-
sified using World Health Organization guidelines55: micro-
scopically detected infections during follow-up were classified
as recurrent; recurrent infections sharing with blood samples
taken at day 0 PCR bands in polymorphic merozoite antigens
or microsatellite fragment sizes were classified as recrudes-
cent, and recurrent infections not sharing PCR bands or
microsatellite fragment sizes with blood samples taken at
day 0 were classified as re-infections (new infections). Molecular
markers were coded as either single or mixed allele genotypes in
the case of SNPs and as mean copy number per sample for copy
number polymorphisms. Multi-SNP haplotypes were recon-
structed as described in the Molecular DMSAP.56,57
Statistical analysis. All statistical analyses were conducted
by using Stata 11 (StataCorp LP, College Station, TX). The
primary endpoint was clinical efficacy, defined as the PCR-
adjusted risk of P. falciparum recrudescent infections. The
cumulative risk of recrudescence at day 28 and day 42 was
computed by using survival analysis (Kaplan-Meier estimates
[K-M]). Comparisons of K-M survival curves were performed
by using log rank tests stratified by study sites.
Multivariable analysis of risk factors associated with PCR-
adjusted recrudescence was conducted by using Cox propor-
tional hazards regression models with shared frailty parameters
to adjust for site-specific effects. The risk factors that affect
Figure 1. Patient flow chart for study of parasite risk factors that affect treatment outcomes for Plasmodium falciparum malaria after
treatment with artemether-lumefantrine (AL) or artesunate-amodiaquine (ASAQ).
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the clinical efficacy of AL and ASAQ have been intensively
studied in pooled analyses of both ACTs. Sixty-two studies
with 14,679 patients treated with AL and 39 studies with
7,652 patients treated with ASAQ were analyzed; these full
analyses have been submitted for publication. The univariable
and multivariable risk factors identified in those studies are
shown in Supplemental Tables 1 and 2. Clinical covariates
in the current study were included based on the previous
analyses as follows: (lumefantrine or amodiaquine dose, enrol-
ment parasitemia, age category, and ASAQ fixed or co-blistered
versus loose formulation (Table 1). Each molecular marker was
then added to the model. The proportional hazard assumption
was tested based on residuals of Schoenfeld.58 In the case of
non-proportionality, interactions with a categorized time vari-
able based on clinical follow-up intervals (< day 14, days 14–21,
21–28, and > day 28) were used to account for changing effects
over time, and neighboring windows with similar effects of
genetic covariates as determined by Wald test were merged.
Finally, other covariates (transmission intensity, region of
sample origin, dose supervision, and fat intake) were included
in the model if they improved model fit based on the likelihood
ratio test. Multiplicity of infection was only available for 197
and 141 AL and ASAQ patients, respectively, and was
excluded from further analysis. The final model was then used
to estimate the adjusted hazard ratio for recrudescence in
patients who carried parasites with resistant versus sensitive
genotypes on day 0. The assumption of proportional hazards
was tested separately for the individual covariates in the final
multivariable model, and any violations were reported.
In patients who had recurrent parasitemia on or before
day 42, changes in pfcrt and pfmdr1 alleles between pre-
treatment and post-treatment matched pairs of samples was
compared by using McNemar’s test. Changes in genotype,
rather than presence of a particular allele, were compared
between matched pairs to ensure that differences reflected
selection rather than underlying differences in allele frequencies
among populations. The effect of markers present at the time
of recurrence on median time to PCR-adjusted re-infection
(new infection) was investigated by using the Wilcoxon
Mann-Whitney U test. Competing risk analysis59 was used to
estimate cumulative incidence of PCR-adjusted re-infections
with specific genotypes, where recrudescent and re-infections
with other genotypes were treated as competing events.
The number of molecular markers used to distinguish
recrudescence from re-infection varied from one to three or
more loci. The effect of the number of loci genotyped on
outcome classification was investigated in a regression model
of predictors of recrudescence within all recurrences. No effect
of this variable was observed on the number of recrudescent
infections identified among recurrences in univariable or multi-
variable analysis, it was not further investigated.
RESULTS
Individual patient and linked parasite genotype data from
31 studies were available (Supplemental Table 3). Data from
7,249 patients who were treated with AL (5,003) or ASAQ
(2,246) were included in the analysis. Twenty seven studies
were published, representing 91% of all published clinical
data on AL and ASAQ in which pfcrt or pfmdr1 genotypes
were determined. Baseline characteristics for patients treated
with AL or ASAQ are shown in Supplemental Table 4.
Clinical efficacy of AL and ASAQ. The estimates of effi-
cacy (defined as risk of PCR-adjusted recrudescence) of AL
and ASAQ are shown in Table 2. Of the 5,003 AL patients,
4,763 were followed-up for at least one day and were included
in the analysis. Similarly, of the 2,246 ASAQ patients, 2,099
were included. In total, 1,107 patients had recurrent parasitemia
after treatment with AL, of which 188 (18%) were classified
by PCR as having recrudescent infections. The corresponding
figures for ASAQ showed that 484 patients had recurrent
parasitemia and 58 (12%) were confirmed as having recrudes-
cent infections. The overall clinical efficacy at day 42 was
94.8% (95% confidence interval [CI] = 94–95.5%) in patients
treated with AL and 95.1% (95% CI = 92.3–96.7%) in
patients treated with ASAQ (Table 2). The proportion of
adequate clinical and parasitologic response of ASAQ was
significantly higher for the fixed dose and co-blistered tablets
(97.0%, 95% CI = 94.4–98.4%) compared with the loose for-
mulation (93.0%, [95% CI = 89.2–95.6) (P = 0.003).
Baseline prevalence of genetic markers associated with
resistance. The baseline prevalence of SNPs in pfcrt and
pfmdr1 was determined, but not all SNPs were available for
all isolates. The most frequently analyzed SNPs were position
76 in pfcrt determined for 3,640 patients and position 86 in
pfmdr1 for 3,580 patients, with the complete haplotype of
positions 72–76 in pfcrt, pfmdr1 copy number, and SNPs at
positions pfmdr1 184, 1034, 1042, and 1246 available in a
subset of patients (Table 3).
The prevalence of pfcrt and pfmdr1 alleles varied by region
(Table 3). The pfcrt 76T allele (all in the SVMNT haplotype)
was almost fixed at 96.4% (81/84) in isolates from Asia
(Thailand) and Oceania (Papua New Guinea). In Africa, the
only resistant haplotype observed was the CVIET allele. The
76T allele predominated: 67.6% (1,155/1,708) in East Africa
and 73.3% (1,354/1,848) inWest Africa (Table 3). Amplification
of pfmdr1 was seen in 50% (88/176) of isolates from Asia
Table 1
Multivariable risk factors for PCR-adjusted recrudescent infections
for persons treated with artemether-lumefantrine and artesunate-
amodiaquine at day 42*
Treatment and variable Adjusted HR [95% CI] P
AL (n = 14,679; 371 recrudescences)
Age category: ³ 12 years (reference)
< 1 1.55 (0.86–2.78) 0.150
1 to < 5 2.38 (1.51–3.75) < 0.001
5 to < 12 1.39 (0.86–2.23) 0.160
Enrollment parasite density (log scale) 1.13 (1.05–1.23) 0.002
Lumefantrine dose (mg/kg) 1.00 (0.99–1.01) 0.860
ASAQ (n = 7,652; 220 recrudescences)
Age category: ³ 12 years (reference)
< 1 2.20 (1.01–4.78) 0.047
1 to < 5 2.27 (1.13–4.55) 0.021
5 to < 12 1.51 (0.72–3.17) 0.140
Enrollment parasite density (log scale) 1.50 (1.16–1.93) 0.002
Amodiaquine dose (mg/kg) 0.92 (0.82–1.04) 0.180
Drug formulation: fixed dose
(reference)
Co-blistered 0.98 (0.41–2.32) 0.960
Loose 2.94 (1.58–5.48) 0.001
*Risk factors were selected based upon previous analysis of the same data set (“The effect
of dosing strategies on the antimalarial efficacy of artemether-lumefantrine: a pooled analysis
of individual patient data, by the WWARN AL Study Group” presubmission approved at
PLoS Medicine, March 28, 2014 and “The Effect of Dosing Strategies on the Therapeutic
Efficacy of Artesunate Amodiaquine for uncomplicated malaria: A Pooled Analysis of
Individual Patient Data” in preparation). Values in bold are statistically significant. PCR =
polymerase chain reaction; HR = hazards ratio; CI = confidence interval; AL = artemether-
lumefantrine; ASAQ = artesunate-amodiaquine.
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examined for this genotype, but only in 2.6% (17/659) of iso-
lates from Africa. Pfmdr1 86Y was found in 29.2% (66/226) of
isolates from Asia/Oceania; in contrast, the 86Y allele was
present in 61.1% (1247/2033) of isolates from East Africa
and 48.7% (643/1321) of isolates from West Africa.
The SNPs at positions 184 and 1246 showed similar patterns,
with pfmdr1 Y184 and D1246 predominating in all three
regions (Table 3). Almost all isolates examined carried the
pfmdr1 S1034 (760/844) and N1042 (1,053/1,064).
Parasite genotypes as risk factors for recrudescent infection.
After controlling for age, baseline parasite density, and total
lumefantrine dose (Table 1), the presence of parasites in the
initial infection that carried pfmdr1 N86 (alone or a mixed
infection with pfmdr1 86Y) was a significant risk factor for
recrudescent infection occurring between days 14 and 28 after
AL treatment (adjusted hazards ratio [AHR] = 4.74, 95%
CI = 2.29–9.78, P < 0.001) (Table 4 and Figure 2A). Region
of sample origin was not included as a covariate in the model
because it violated the assumption of proportional hazards.
The risk associated with presence of pfmdr1 N86 remained
significant when excluding infections with multiple copies of
pfmdr1 (AHR = 3.93, 95% CI = 1.90–8.94, P < 0.001). The
region of sample origin interacted significantly with pfmdr1
N86, showing that the marker had a larger effect in Asia
(AHR = 14.06, 95% CI = 4.52–43.74, P < 0.001) than in Africa
(AHR = 3.72, 95% CI = 1.77–7.79, P = 0.001). However, this
interaction violated the proportional hazards assumption
since there were so few samples in Africa that had multiple
copies of pfmdr1, and this variable was excluded from the
final model.
The presence of more than one copy of pfmdr1 was a signif-
icant risk factor for recrudescence occurring between days 14
and 21 after AL treatment (AHR = 5.81, 95% CI = 2.38–14.21,
P < 0.001) (Figure 2B). When the effect of region of origin was
added to the model, patients with parasites carrying multiple
copy numbers of pfmdr1 were associated with an increased
risk of recrudescence before day 14 (AHR = 83.56, 95% CI =
7.43–939.70, P < 0.001) as well as between days 14 and 21
(AHR = 18.54 (95% CI = 7.61–45.19, P < 0.001) (Table 4).
The interaction of region of origin with pfmdr1 copy number
could not be investigated because of insufficient multicopy
samples from Africa in the model.
When pfmdr1 N86 and pfmdr1 copy number were included
in the same model, region of sample origin was no longer a
significantly predictive covariate in the multivariable analysis
or as an interaction term with either genotype. Both markers
remained as significant predictors of recrudescent infection,
between days 14 and 28 for pfmdr1 N86 (AHR = 5.98, 95%
CI = 1.68–21.36, P = 0.006) and days 14 and 21 for multiple
Table 3
Baseline (pre-treatment) prevalence of genetic markers associated
with drug resistance*
Marker Asia/Oceania East Africa West Africa
pfcrt 76
Sample size 84 1,708 1,848
K 3 (4) 553 (32) 494 (27)
K/T 2 (2) 125 (7) 249 (13)
T 79 (94) 1,030 (60) 1105 (60)
pfcrt 72–76
Sample size 84 155 84
CVMNK 3 (4) 37 (24) 14 (17)
CVIET 0 117 (75) 53 (63)
SVMNT 79 (94) 0 0
Mixed 2 (2) 1 (1) 17 (20)
pfmdr1 86
Sample size 226 2,033 1,321
N 160 (71) 759 (37) 678 (51)
N/Y 0 378 (19) 190 (14)
Y 66 (29) 896 (44) 453 (34)
pfmdr1 184
Sample size 228 1,275 686
Y 183 (80) 803 (63) 287 (42)
Y/F 8 (4) 130 (10) 77 (11)
F 37 (16) 342 (27) 322 (47)
pfmdr1 1246
Sample size 77 1,017 687
D 67 (87) 454 (45) 526 (77)
D/Y 10 (13) 309 (30) 86 (13)
Y 0 254 (25) 75 (11)
pfmdr1 86 + 1246
Sample size 69 1,000 685
N D 12 (17) 129 (13) 263 (38)
N Y 0 9 (1) 2 (0)
Y D 50 (72) 248 (25) 199 (29)
Y Y 0 220 (22) 71 (10)
Mixed 7 (10) 394 (39) 150 (22)
pfmdr1 copy number
Sample size 176 659 0
1 88 (50) 642 (98) 0
2 57 (32) 16 (2) 0
> 2 31 (18) 1 (0) 0
*Values are no. (%). pfcrt = Plasmodium falciparum chloroquine resistance transporter gene;
pfmdr1 = P. falciparum multidrug resistance 1 (pfmdr1) gene.
Table 2
PCR-adjusted adequate clinical and parasitologic response for patients treated with of artemether-lumefantrine and artesunate-amodiaquine
after 42 days of follow-up*
Variable AL
ASAQ fixed dose
and co-blistered ASAQ loose
No. at risk 4,763 1,113 986
ACPR by group, % (95% CI)
Age category, years
< 1 96.7 (92.7–98.5) 100 85.2 (70.5–93.0)
1 to < 5 93.6 (92.0–94.8) 96.4 (93.2–98.1) 93.8 (90.0–96.2)
5–12 96.3 (94.5–97.5) 98.8 (91.6–99.8) 99 (96.1–99.8)
³ 12 95.2 (93.8–96.3) – –
Region
Asia/Oceania 95.2 (93.8–96.2) – –
East Africa 93.8 (92.4–95.0) 100† 91.2 (88.0–94.7)
West Africa 96.2 (94.6–97.3) 96.9 (94.2–98.3) 99.2 (96.8–99.8)†
Overall 94.8 (94.0–95.5) 97.0 (94.4–98.4) 93.0 (89.2–95.6)
*PCR = polymerase chain reaction; ACPR = adequate clinical and parasitologic response; AL = artemether-lumefantrine; ASAQ = artesunate –amodiaquine; CI = confidence interval.
†Followed-up to day 28.
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copies of pfmdr1 (AHR = 6.52, 95% CI = 2.36–17.97, P < 001);
Table 4).
No association was observed between the pfmdr1 184,
pfmdr1 1246, and pfcrt polymorphisms and recrudescent
infections after AL treatment. The risk for parasites with the
pfmdr1 N86 + D1246 haplotype is not reported here because
it represents a subset of the pfmdr1 N86 sample set (of the
samples genotyped for both SNPs, all but 17 samples with
pfmdr1 N86 also had D1246). For patients treated with
ASAQ, none of the analyzed pfcrt or pfmdr1 parasite geno-
types were significant risk factors for recrudescent infections
in the multivariable analysis.
Post-treatment selection of genetic markers associated with
resistance. To examine changes in the genotypes of parasites
after drug treatment, we compared the prevalence of pfmdr1
and pfcrt alleles in paired isolates from the initial and the
recurrent parasites in the subset of patients in whom parasites
recurred during the 42 day follow-up period. Post-treatment
changes among specific genotypes are shown in Table 5 for all
recurrent infections. Significant selection of pfcrt K76, and
pfmdr1 N86 occurred in recrudescent and re-infecting para-
sites after AL treatment. Selection of pfmdr1 184F and D1246
alleles was also observed in the recurrent parasites and
pfmdr1 D1246 in those that reinfected patients after treat-
ment. Selection of single or multiple copies of pfmdr1
was not observed in any of the groups (Table 5). Pfmdr1
86Y and 1246Y were significantly selected in recurrent and
re-infections after treatment with ASAQ (Table 5).
Median time to re-infection. The genotype of parasites at
the time of re-infection provides another metric of their sus-
ceptibility to a drug. This analysis indicated that in patients
treated with AL, re-infecting parasites carrying pfmdr1 N86,
pfmdr1 D1246, or pfcrt K76 alleles appeared earlier than
those carrying pfmdr1 86Y, pfmdr1 1246Y, or pfcrt 76T
(Figure 3A). Correspondingly, in patients treated with AL,
parasites carrying pfmdr1N86 had amedian time to re-infection
of 28 days (interquartile range = 21–35 days) compared with
35 days (interquartile range = 28–42 days) for those with pfmdr1
86Y (P < 0.001). Similar differences in the time to re-infection
were observed for patients infected with parasites that carried
the pfmdr1 184F (P = 0.008) or pfcrt K76 alleles (P = 0.001)
compared with pfmdr1 Y184 or pfcrt 76T.
In contrast, in patients treated with ASAQ, parasites carry-
ing pfmdr1 86Y, pfmdr1 1246Y, or pfcrt 76T appeared earlier
after treatment than those carrying pfmdr1 N86, pfmdr1
D1246 or pfcrt K76 (Figure 3B). Parasites with pfcrt 76T had
a median reinfection day of 28 (interquartile range = 21–35)
compared with day 37.5 (interquartile range = 28–42) for
Table 4
Multivariable risk factors for PCR-adjusted recrudescent infections of persons treated with artemether-lumefantrine on day 42*
Marker and variable Adjusted hazard ratio (95% CI) P
pfmdr1 86 (n = 2,543; 135 recrudescent infections)†
pfmdr1 N86 or N/Y
In recrudescence up to day 14 0.79 (0.25–2.54) 0.694
In recrudescence between days 14 and 28 4.74 (2.29–9.78) < 0.001
In recrudescence after day 28 0.84 (0.43–1.66) 0.624
Enrollment parasite density (loge – scale) 1.13 (0.99–1.29) 0.056
Age category (reference < 1 year)
1 to < 5 1.05 (0.40–2.75) 0.922
5 to < 12 0.85 (0.30–2.38) 0.752
³ 12 0.77 (0.25–2.36) 0.647
Lumefantrine dose (mg/kg) 0.99 (0.98–1.00) 0.109
pfmdr1 copy number (n = 808; 73 recrudescent infections)
pfmdr1 copy number > 1‡
In recrudescence up to day 14 83.56 (7.43–939.70) < 0.001
In recrudescence between days 14 and 21 18.54 (7.61–45.19) < 0.001
In recrudescence after day 21 0.61 (0.25–1.51) 0.286
Region (reference Africa)
Asia/Oceania 5.09 (1.06–24.38) 0.042
Enrollment parasite density (loge – scale) 1.00 (0.85–1.18) 0.978
Age category (reference < 5 years)
5 to < 12 0.62 (0.22–1.77) 0.368
³ 12 0.56 (0.16–1.93) 0.359
Lumefantrine dose (mg/kg) 0.98 (0.96–1.00) 0.113
pfmdr1 86 and copy number (n = 719; 59 recrudescent infections)§
pfmdr1 N86 or N/Y
In recrudescence up to day 14 1.00 (0.07–13.64) 0.997
In recrudescence between days 14 and 28 5.98 (1.68–21.36) 0.006
In recrudescence after day 28 0.51 (0.18–1.47) 0.21
pfmdr1 copy number > 1
In recrudescence up to day 14 2.17 (0.16–29.77) 0.561
In recrudescence between days 14 and 21 6.52 (2.36–17.97) < 0.001
In recrudescence after day 21 0.94 (0.31–2.82) 0.916
Enrollment parasite density (loge – scale) 1.08 (0.92–1.28) 0.348
Age category (reference < 5 years)
5 to < 12 1.46 (0.59–3.57) 0.413
³ 12 0.79 (0.27–2.33) 0.663
Lumefantrine dose (mg/kg) 0.98 (0.95–1.00) 0.05
*Values in bold are statistically significant. PCR = polymerase chain reaction; CI = confidence interval; pfmdr1 = P. falciparum multidrug resistance 1 (pfmdr1) gene.
†Region not included as a covariate or interaction term with pfmdr1 86 genotype because proportional hazards assumption was not met.
‡Sparse data for pfmdr1 copy number in Africa prevented the inclusion of region as an interaction term.
§Region as a covariate and region-genotype interaction terms did not have statistically significant effects in this model.
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those carrying K76 (P = 0.053) and those with pfmdr1 1246Y
re-infected on a median day of 21 (interquartile range = 21–28)
compared with day 28 (interquartile range = 21–35) for those
with D1246 (P = 0.001).
DISCUSSION
This pooled analysis of data from 31 clinical studies shows
clearly that the genotypes of infecting parasites influence the
outcome of AL treatment. Patients infected with parasites that
carried the pfmdr1 N86 allele or increased pfmdr1 copy num-
ber were at significantly greater risk of treatment failure than
those whose parasites carried the 86Y allele or a single copy of
pfmdr1. Analysis of the clinical outcomes after treatment with
ASAQ did not link a particular genotype with treatment fail-
ure in this smaller data set. However, it did show clear evidence
of selection of particular parasite genotypes. Our findings are
consistent with those of previous molecular studies in which
changes in the prevalence in the parasite population of partic-
ular alleles of pfcrt or pfmdr1 have been documented in
response to introduction or increased use of lumefantrine
25–35 or amodiaquine.15,28,40–51
Our observation that parasites with the pfmdr1 N86,
D1246, and pfcrt K76 alleles re-infected patients earlier after
AL treatment, and parasites carrying the pfmdr1 86Y, 1246Y,
and pfcrt 76T alleles re-infected patients earlier after ASAQ
is also congruent with the molecular studies. These differ-
ences suggest that parasites with these genotypes can with-
stand higher drug concentrations compared with parasites
that carry the alternative alleles. Recently, Malmberg and
others33 demonstrated this effect quantitatively. After AL
treatment, parasites with the pfmdr1 N86/184F/D1246 haplo-
type were able to re-infect patients whose lumefantrine blood
concentrations were 15-fold higher than was the case for par-
asites carrying the 86Y/Y184/1246Y haplotype,33 providing a
potential pharmacologic explanation for the molecular findings.
Figure 2. Polymerase chain reaction–adjusted efficacy as assessed
by Kaplan-Meier survival estimates for artemether-lumefantrine (AL)
by Plasmodium falciparum multidrug resistance 1 (pfmdr1) genotype
of initial parasites. Dotted line indicates World Health Organization–
recommended 90% efficacy cutoff value for antimalarial drugs.
Clinical response of patients with parasites that carry A, pfmdr1
86Y (blue) versus 86N or N/Y (red); n = 2,543 patients at risk and
B, pfmdr1 copy number > 1 (yellow) versus single copy (green);
n = 808 patients.
Table 5
Selection of pfcrt and pfmdr1 genotypes after treatment with artemether-lumefantrine and artesunate-amodiaquine*
Marker Genotype
Recurrence Recrudescence Re-infection
AL ASAQ AL ASAQ AL ASAQ
pfcrt 76 K! T† 16% (89/571) 10% (25/237) 5% (4/73) 20% (7/35) 17% (82/493) 9% (17/196)
T! K 30% (171/571) 8% (18/237) 25% (18/73) 11% (4/35) 31% (152/493) 7% (14/196)
No change 54% (311/571) 82% (194/237) 70% (51/73) 69% (24/35) 53% (259/493) 84% (165/196)
P value < 0.001 0.286 0.004 (exact) 0.366 < 0.001 0.590
pfmdr1 86 N! Y 13% (95/712) 27% (92/341) 10% (10/101) 18% (5/28) 14% (85/609) 28% (87/308)
Y! N 40% (286/712) 16% (54/341) 31% (31/101) 14% (4/28) 42% (255/609) 16% (49/308)
No change 46% (331/712) 57% (195/341) 59% (60/101) 68% (19/28) 44% (269/609) 56% (172/308)
P value < 0.001 0.002 0.001 0.739 < 0.001 0.001
pfmdr1 184 Y! F 24% (74/311) 12% (37/303) 20% (14/69) 12% (3/25) 25% (60/242) 12% (34/273)
F! Y 16% (51/ 311) 17% (50/303) 14% (10/69) 4% (1/25) 17% (41/242) 18% (49/273)
No change 60% (186/311) 71% (216/303) 65% (45/69) 84% (21/25) 58% (141/242) 70% (190/273)
P value 0.040 0.163 0.414 0.625 0.059 0.100
pfmdr1 1246 D! Y 14% (38/273) 32% (102/317) 11% (5/44) 39% (11/28) 15% (33/227) 32% (90/284)
Y! D 32% (86/273) 19% (60/317) 30% (13/44) 14% (4/28) 32% (73/227) 20% (56/284)
No change 54% (149/273) 49% (155/317) 59% (26/44) 46% (13/28) 53% (121/227) 48% (138/284)
P value < 0.001 0.001 0.059 0.119 < 0.001 0.005
pfmdr1 copy number 1! 2 or more 1% (2/269) – 4% (2/53) – 0 –
2 or more! 1 1% (3/269) – 2% (1/53) – 1% (2/216) –
No change 98% (264/269) – 94% (50/53) – 99% (214/216) –
P value 1.000 (exact) 1.000 (exact) 0.500 (exact)
*Values in bold indicate statistically significant selection (P < 0.05) by using McNemar’s paired test. Those marked exact were tested by using the exact distribution for small sample sizes.
A small number of recurrent infections (4 for AL and 6 for ASAQ) were not polymerase chain reaction–adjusted and were excluded from the analysis of recrudescent and re-infections. pfcrt =
Plasmodium falciparum chloroquine resistance transporter gene; pfmdr1 = P. falciparummultidrug resistance 1 (pfmdr1) gene; AL = artemether-lumefantrine; ASAQ = artesunate –amodiaquine.
†Each category includes all changes from one allele to another. For example, K! T includes K! T, K! K/T, and K/T! T changes.
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Together, these observations suggest that monitoring shifts to
earlier time of re-infection could provide a relatively simple
warning of decreasing susceptibility to these drugs, especially if
combined with timed measurement of drug concentrations in
patients’ blood.
In Southeast Asia, parasites with increased pfmdr1 copy
number are common in areas where mefloquine has been
intensively deployed,36 and almost half of the samples in our
data set from that region had at least two copies of the gene.
Increased pfmdr1 copy number was rarely observed in our
large sample of isolates from Africa, populations that have
had little exposure to mefloquine. Lumefantrine has a shorter
half-life in patients than mefloquine,60 and may not exert an
equivalently strong selection for copy number increase. How-
ever, in areas where mefloquine is being introduced, close
attention to pfmdr1 copy number is clearly warranted. A
recent report of parasites in Ghana with increased pfmdr1
copy number underscores the importance of including this
parameter in molecular surveillance.61
This study supported the conclusion that parasites with
increased copy number of pfmdr1 are also less sensitive to
lumefantrine.37–40 In Southeast Asia, the amplified alleles
almost always carried the N86 allele of pfmdr1.34,36,62 How-
ever, this was not the case in the few parasites from Africa in
our data set that did have an increased copy number31 so
either of the N86Y alleles of pfmdr1 can apparently be ampli-
fied. It is also important to note that increased copy number
and the presence of the pfmdr1 N86 allele were independent
risk factors for treatment failure in our analysis.
The evidence of strong selection of particular alleles by
both drugs in recurrent parasites, coupled with our observa-
tion that particular parasite genotypes increase risk of treat-
ment failure, demonstrates that tracking these molecular
markers can signal early decreases in susceptibility to
lumefantrine or amodiaquine. Both alleles of pfmdr1 N86Y,
Y184F, and D1246Y are common in P. falciparum popula-
tions in Africa, and pfcrt K76 has increased in prevalence in
recent years. Thus, changes in the prevalence of these alleles
can be a sensitive indicator of selection of parasite popula-
tions by AL and ASAQ. In turn, decreasing efficacy of these
partner drugs exposes the artemether or artesunate component
of the ACT to selective pressure and could facilitate emer-
gence of new foci of resistance to artemisinin, as observed in
the Mekong region. The recent identification of a marker cor-
related with slow response to artemisinin,63 will also enable
molecular assessment of this trend.
Application of these molecular tools is increasingly feasible
in the context of clinical trials and in community surveys of
populations where AL or ASAQ are heavily used. These
approaches can offer cost-effective methods that detect evi-
dence of declines in parasite susceptibility far earlier than
before, enabling detailed studies of clinical responses to the
drugs in areas of concern. This two-stage approach can pro-
vide an opportunity for policy makers to manage emerging
Figure 3. A, Cumulative (left panels) and relative (right panels) risks of polymerase chain reaction (PCR)–adjusted reinfection for baseline
Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genotypes after artemether-
lumefantrine treatment, in which recrudescent and re-infections with other genotypes were treated as competing events. B, Cumulative (left panels)
and relative (right panels) risks of PCR-adjusted re-infection for baseline pfcrt and pfmdr1 genotypes after artesunate-amodiaquine treatment,
in which recrudescent and re-infections with other genotypes were treated as competing events.
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threats of resistance before clinical failure of a drug is mani-
fest and preserve the useful therapeutic life of these valuable
antimalarial drugs for as long as possible.
Finally, these results suggest that AL and ASAQ interact
with the proteins encoded by pfcrt and pfmdr1, but the two
drugs select alternative alleles. Two recent publications have
also demonstrated that piperaquine exerts selection pressure
on these genes in the same direction as amodiaquine, suggest-
ing that the newer ACT, dihydroartemisinin-piperaquine
could also function as a counterweight to lumefantrine.64,65
This opposing selection of parasite genotypes by the partner
drugs could influence the choice of an ACT in regions
with different patterns of pfcrt and pfmdr1 polymorphisms.
For example, if a particular allele is rapidly increasing
under intensive use of AL, ASAQ or dihydroartemisinin-,
piperaquine might be introduced to counteract that trend.
Concurrent use of two ACTs that exert opposing selective
pressures on recurrent parasites could provide a counterbal-
ance and prevent strong directional selection in pfcrt and
pfmdr1, maintaining the overall efficacy of AL and ASAQ
for a long period. Despite logistical challenges, the simulta-
neous use of multiple first line therapies is supported by math-
ematical models,66–68 and concurrent availability of AL and
ASAQ, as implemented in some countries in West Africa4
may provide a practical means to test this strategy directly.
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